Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Federico

Showing results (121-130 of 271) with videos related to

Pageof 28
Sort By:
American Journal of Hematology|January 12, 2008
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemiasMaria Goldaniga, Andrea Ferrario, Sergio Cortelazzo, et al.
Oncology Reports|March 17, 2009
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphomaPaolo G Gobbi, Francesco Valentino, Marco Danova, et al.
Haematologica|August 13, 2013
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab eraTamar Tadmor, Alessia Bari, Stefano Sacchi, et al.
Mayo Clinic Proceedings|June 6, 2015
Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 PatientsTamar Tadmor, Alessia Bari, Luigi Marcheselli, et al.
Oncotarget|September 1, 2018
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applicationsAngela Toss, Federico Piacentini, Laura Cortesi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei LinfomiLuca Baldini, Maura Brugiatelli, Stefano Luminari, et al.
European Journal of Haematology|February 3, 2006
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 studyMassimo Federico, Stefano Luminari, Paolo G Gobbi, et al.
Leukemia & Lymphoma|April 11, 2003
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL)Marco Lombardo, Fortunato Morabito, Francesco Merli, et al.
Annals of Hematology|March 19, 2026
Treatment of Burkitt lymphoma in real-world setting: findings on 104 consecutive cases diagnosed and treated in Kazakhstan over the last decadeAkmaral Jazyltayeva, Nazarii Shokun, Ayazhan Umutbayeva, et al.
Hematological Oncology|July 27, 2007
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern ItalyStefano Luminari, Marina Cesaretti, Ivan Rashid, et al.
Pageof 28

Showing results (121-130 of 271) with videos related to

Sort By:
Pageof 28
American Journal of Hematology|January 12, 2008
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemiasMaria Goldaniga, Andrea Ferrario, Sergio Cortelazzo, et al.
Oncology Reports|March 17, 2009
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphomaPaolo G Gobbi, Francesco Valentino, Marco Danova, et al.
Haematologica|August 13, 2013
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab eraTamar Tadmor, Alessia Bari, Stefano Sacchi, et al.
Mayo Clinic Proceedings|June 6, 2015
Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 PatientsTamar Tadmor, Alessia Bari, Luigi Marcheselli, et al.
Oncotarget|September 1, 2018
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applicationsAngela Toss, Federico Piacentini, Laura Cortesi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei LinfomiLuca Baldini, Maura Brugiatelli, Stefano Luminari, et al.
European Journal of Haematology|February 3, 2006
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 studyMassimo Federico, Stefano Luminari, Paolo G Gobbi, et al.
Leukemia & Lymphoma|April 11, 2003
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL)Marco Lombardo, Fortunato Morabito, Francesco Merli, et al.
Annals of Hematology|March 19, 2026
Treatment of Burkitt lymphoma in real-world setting: findings on 104 consecutive cases diagnosed and treated in Kazakhstan over the last decadeAkmaral Jazyltayeva, Nazarii Shokun, Ayazhan Umutbayeva, et al.
Hematological Oncology|July 27, 2007
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern ItalyStefano Luminari, Marina Cesaretti, Ivan Rashid, et al.
Pageof 28